FDA Approves Lower Dose of Cabazitaxel for Prostate Cancer

September 19, 2017

The FDA approved a 20 mg dose of cabazitaxel for treatment of prostate cancer, based on data from a multicenter trial involving 1,200 patients with metastatic prostate cancer previously treated with a docetaxel-containing regimen.

The trial showed similar overall survival rates for patients treated with the dose compared to the 25 mg dose approved in 2010.

The new recommended dosage is administered every three weeks in combination with a daily regimen of 10 mg oral prednisone.

View today's stories